3003新葡的京集团
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2019.12.03
关于为2019年面向合格投资者公开发行公司债券(第二期)追加增信措施并提供反担保的公告...
2019.12.03
第四届董事会第二十六次会议决议公告
2019.12.03
第四届监事会第二十一次会议决议公告
2019.12.03
关于独立董事辞职的公告
2019.12.03
关于召开2019年第四次临时股东大会的通知公告
2019.12.03
独立董事候选人声明(吕川)
2019.11.21
关于对深圳交易所问询函回复的公告
2019.11.13
五矿有限公司关于公司2019年面向合格投资者公开发行公司债券(第一期)2019年第一次...
2019.11.13
华融股份有限公司关于公司2019年度累计新增借款超过上年末净资产的百分之四十的受...
2019.11.07
关于“163003新葡的京集团”公司债券回售结果的公告
第一页
上一页
41
42
43
44
45
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.